Company Of The Day: Merck

+6.30%
Upside
93.13
Market
99.00
Trefis
MRK: Merck logo
MRK
Merck

What?

The Wall Street Journal reports that Merck (NYSE:MRK) is looking to buy Acceleron Pharma, in a deal that could be announced as soon as this week.

Why?

Relevant Articles
  1. Is There A Better Pick Over Merck Stock In Animal Health Space?
  2. Will Merck Stock Rise After Its Q1 Results?
  3. Company Of The Day: Merck
  4. What’s Next For Merck Stock After A 6% Fall In A Month?
  5. Will Merck Stock Rise After Its Q4 Results?
  6. Here’s A Better Pharmaceutical Pick Over Merck Stock

A deal could bolster Merck’s rare diseases business. Acceleron’s most high-profile development is an experimental drug for pulmonary arterial hypertension, a respiratory disease.

So What?

While the deal would be one of Merck’s largest ever, it probably isn’t too big in the context of Merck’s market cap. XLRN had a market cap of about $11 billion as of Monday, compared to MRK’s $185 billion market cap.

See Our Complete Analysis For Merck

Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates